shutterstock_1960556293_molly_woodward
Molly Woodward / Shutterstock.com
9 August 2022AmericasStaff Writer

Pfizer bolsters haematology expertise with $5.4bn deal

Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
28 June 2022   Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.
Americas
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Big Pharma
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division

More on this story

Big Pharma
28 June 2022   Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.
Americas
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Big Pharma
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division

More on this story

Big Pharma
28 June 2022   Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.
Americas
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Big Pharma
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division